rHGG SDT
Phase 0/1
Clinical Trial
Dr. Nader Sanai is conducting a Phase 0/1 clinical trial in recurrent high-grade gliomas (rHGG)
Nader Sanai, MD, Director of the Ivy Brain Tumor Center is conducting the first clinical trial of Sonodynamic Therapy (SDT) with SONALA-001 at the Ivy Brain Tumor Center at Barrow Neurological Institute. The Ivy Brain Tumor Center and SonALAsense have announced positive proof of concept in the first-in-human Phase 0/1 clinical trial of SDT in rHGG patients.
The initial results indicate SDT rapidly leads to targeted oxidative stress and cell death in human glioma tissue. SDT was well-tolerated in all patients.
For more details visit the ClinicalTrials.gov listing:
Phase 0/1 Clinical Trial Summary
Clinical trial data translated tumor cell death and biomarkers predictive of survival extension from non-clinical studies to recurrent high-grade glioma (rHGG) patients. SDT was well-tolerated and not associated with off-target effects. As predicted from preclinical models, the effects of SDT on human rHGG show:
-
Immediate cell death and apoptosis (programmed cell death), same mechanism of action as photodynamic therapy (PDT)
-
Rapidity of action (within 96 hours), similar to PDT
-
These biomarker results may indicate a high probability of increased survival in our Phase 2 SDT-202 trial in recurrent glioblastoma (rGBM) as seen in animal glioma models treated with ALA SDT and as reported for clinical trials of ALA PDT